Top

Published in:

Open Access 30-07-2022 | Original Research Article

Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment

Authors: Vidya Perera, Grigor Abelian, Danshi Li, Zhaoqing Wang, Liping Zhang, Susan Lubin, Akintunde Bello, Bindu Murthy

Published in: Clinical Pharmacokinetics | Issue 10/2022

Abstract

Objective

The aim of this study was to assess the effect of moderate or severe renal impairment on the pharmacokinetic (PK) properties of milvexian.

Methods

This open-label, parallel-group study assessed the PK, safety, and tolerability of a single oral 60 mg dose of milvexian in participants with normal renal function (n = 8; estimated glomerular filtration rate [eGFR] ≥ 90 mL/min/1.73 m²) and participants with moderate (n = 8; eGFR ≥ 30 to ≤ 59 mL/min/1.73 m²) or severe (n = 8; eGFR < 30 mL/min/1.73 m²) renal impairment. Regression analysis was performed using linear regression of log-transformed PK parameters versus eGFR.

Results

Milvexian was well tolerated, with no deaths, serious adverse events, or serious bleeding reported. The maximum milvexian concentration (C_max) was similar for all groups. Based on a regression analysis of milvexian concentration versus eGFR, participants with eGFR values of 30 and 15 mL/min/1.73 m², respectively, had area under the curve (AUC) values that were 41% and 54% greater than in participants with normal renal function. Median time to maximum concentration (T_max) was similar for the three groups (4.5–5.0 h). The half-life increased for participants with moderate (18.0 h) or severe (17.7 h) renal impairment compared with those with normal renal function (13.8 h).

Conclusion

A single dose of milvexian 60 mg was safe and well tolerated in participants with normal renal function and moderate or severe renal impairment. There was a similar increase in milvexian exposure between the moderate and severe renal groups.

Clinical Trials Registration

This study was registered with ClinicalTrials.gov (NCT03196206, first posted 22 June 2017).

Available only for authorised users

Cavallari I, Patti G. Efficacy and safety of oral anticoagulation in elderly patients with atrial fibrillation. Anatol J Cardiol. 2018;19(1):67–71. https://doi.org/10.14744/AnatolJCardiol.2017.8256.CrossRefPubMedPubMedCentral

Kapil N, Datta YH, Alakbarova N, Bershad E, Selim M, Liebeskind DS, et al. Antiplatelet and anticoagulant therapies for prevention of ischemic stroke. Clin Appl Thromb Hemost. 2017;23(4):301–18. https://doi.org/10.1177/1076029616660762.CrossRefPubMed

Gurbel PA, Fox KAA, Tantry US, Ten Cate H, Weitz JI. Combination antiplatelet and oral anticoagulant therapy in patients with coronary and peripheral artery disease. Circulation. 2019;139(18):2170–85. https://doi.org/10.1161/CIRCULATIONAHA.118.033580.CrossRefPubMed

Eisen A, Giugliano RP, Braunwald E. Updates on acute coronary syndrome: a review. JAMA Cardiol. 2016;1(6):718–30. https://doi.org/10.1001/jamacardio.2016.2049.CrossRefPubMed

Faxon DP. Use of antiplatelet agents and anticoagulants for cardiovascular disease: current standards and best practices. Rev Cardiovasc Med. 2005;6(Suppl 4):S3-14.PubMed

Bracey A, Shatila W, Wilson J. Bleeding in patients receiving non-vitamin K oral anticoagulants: clinical trial evidence. Ther Adv Cardiovasc Dis. 2018;12(12):361–80. https://doi.org/10.1177/1753944718801554.CrossRefPubMedPubMedCentral

Shpak M, Ramakrishnan A, Nadasdy Z, Cowperthwaite M, Fanale C. Higher incidence of ischemic stroke in patients taking novel oral anticoagulants. Stroke. 2018;49(12):2851–6. https://doi.org/10.1161/STROKEAHA.118.022636.CrossRefPubMed

Naqvi IA, Kamal AK, Rehman H. Multiple versus fewer antiplatelet agents for preventing early recurrence after ischaemic stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2020;(8):CD009716. https://doi.org/10.1002/14651858.CD009716.pub2

Ten Cate H, Hackeng TM, de Frutos PG. Coagulation factor and protease pathways in thrombosis and cardiovascular disease. Thromb Haemost. 2017;117(7):1265–71. https://doi.org/10.1160/TH17-02-0079.CrossRefPubMed

10.

Brass LF. Thrombin and platelet activation. Chest. 2003;124(3 Suppl):18S-25S. https://doi.org/10.1378/chest.124.3_suppl.18s.CrossRefPubMed

11.

Lowenberg EC, Meijers JC, Monia BP, Levi M. Coagulation factor XI as a novel target for antithrombotic treatment. J Thromb Haemost. 2010;8(11):2349–57. https://doi.org/10.1111/j.1538-7836.2010.04031.x.CrossRefPubMed

12.

Emsley J, McEwan PA, Gailani D. Structure and function of factor XI. Blood. 2010;115(13):2569–77. https://doi.org/10.1182/blood-2009-09-199182.CrossRefPubMedPubMedCentral

13.

Salomon O, Steinberg DM, Koren-Morag N, Tanne D, Seligsohn U. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood. 2008;111(8):4113–7. https://doi.org/10.1182/blood-2007-10-120139.CrossRefPubMed

14.

Yang DT, Flanders MM, Kim H, Rodgers GM. Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events. Am J Clin Pathol. 2006;126(3):411–5. https://doi.org/10.1309/QC259F09UNMKVP0R.CrossRefPubMed

15.

Gailani D, Gruber A. Factor XI as a therapeutic target. Arterioscler Thromb Vasc Biol. 2016;36(7):1316–22. https://doi.org/10.1161/ATVBAHA.116.306925.CrossRefPubMedPubMedCentral

16.

Salomon O, Steinberg DM, Zucker M, Varon D, Zivelin A, Seligsohn U. Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. Thromb Haemost. 2011;105(2):269–73. https://doi.org/10.1160/TH10-05-0307.CrossRefPubMed

17.

Pollack CV Jr, Kurz MA, Hayward NJ. EP-7041, a factor XIa inhibitor as a potential antithrombotic strategy in extracorporeal membrane oxygenation: a brief report. Crit Care Explor. 2020;2(9): e0196. https://doi.org/10.1097/CCE.0000000000000196.CrossRefPubMedPubMedCentral

18.

Sakimoto S, Hagio T, Yonetomi Y, Ono T, Koyama S, Hashimoto A, et al. ONO-8610539, an injectable small-molecule inhibitor of blood coagulation factor XIa, improves cerebral ischemic injuries associated with photothrombotic occlusion of rabbit middle cerebral artery. Presented at the International Stroke Conference; 21–24 February 2017; Houston, TX, USA.

19.

Thomas D, Kanefendt FS, Schwers S, Unger S, Yassen A, Boxnick S. First evaluation of the safety, pharmacokinetics and pharmacodynamics of BAY 2433334 a small molecule targeting coagulation factor XIa in healthy young male participants. Presented at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Virtual Congress; 12–14 July 2020.

20.

Weitz JI, Bauersachs R, Becker B, Berkowitz SD, Freitas MCS, Lassen MR, et al. Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial. JAMA. 2020;323(2):130–9. https://doi.org/10.1001/jama.2019.20687.CrossRefPubMedPubMedCentral

21.

Rosenthal RL, Dreskin OH, Rosenthal N. Plasma thromboplastin antecedent (PTA) deficiency; clinical, coagulation, therapeutic and hereditary aspects of a new hemophilia-like disease. Blood. 1955;10(2):120–31.CrossRef

22.

Franchini M, Veneri D, Lippi G. Inherited factor XI deficiency: a concise review. Hematology. 2006;11(5):307–9. https://doi.org/10.1080/10245330600921964.CrossRefPubMed

23.

Lee SE, Choi YJ, Chi SI, Kim HJ, Seo KS. Factor XI deficiency and orthognathic surgery: a case report on anesthesia management. J Dent Anesth Pain Med. 2015;15(1):25–9. https://doi.org/10.17245/jdapm.2015.15.1.25.CrossRefPubMedPubMedCentral

24.

Minnema MC, Friederich PW, Levi M, von dem Borne PA, Mosnier LO, Meijers JC, et al. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest. 1998;101(1):10–4. https://doi.org/10.1172/JCI781.CrossRefPubMedPubMedCentral

25.

Wang X, Smith PL, Hsu MY, Gailani D, Schumacher WA, Ogletree ML, et al. Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. J Thromb Haemost. 2006;4(9):1982–8. https://doi.org/10.1111/j.1538-7836.2006.02093.x.CrossRefPubMed

26.

Preis M, Hirsch J, Kotler A, Zoabi A, Stein N, Rennert G, et al. Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. Blood. 2017;129(9):1210–5. https://doi.org/10.1182/blood-2016-09-742262.CrossRefPubMed

27.

Puy C, Rigg RA, McCarty OJ. The hemostatic role of factor XI. Thromb Res. 2016;141(Suppl 2):S8–11. https://doi.org/10.1016/S0049-3848(16)30354-1.CrossRefPubMedPubMedCentral

28.

Dilger AK, Pabbisetty KB, Corte JR, De Lucca I, Fang T, Yang W, et al. Discovery of milvexian, a high-affinity, orally bioavailable inhibitor of factor XIa in clinical studies for antithrombotic therapy. J Med Chem. 2022;65(3):1770–85. https://doi.org/10.1021/acs.jmedchem.1c00613.CrossRefPubMed

29.

Wong PC, Crain EJ, Dilger AK, Exler RR, Ewing WR, Gordon D, et al. Small-molecule factor XIa inhibitor, BMS-986177/JNJ-70033093, prevents and treats arterial thrombosis in rabbits at doses that preserve hemostasis. Poster PB0121. Presented at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Virtual Congress; 12–14 July 2020.

30.

Wang X, Qiu L, Du F, Shukla N, Nawrocki A, Chintala M. Antithrombotic effects of a novel small molecule FXIa inhibitor BMS-986177/JNJ-70033093 in a rabbit AV-shunt model of thrombosis. Poster PB0179. Presented at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Virtual Congress; 12–14 July 2020.

31.

Perera V, Wang Z, Luettgen J, Li D, DeSouza M, Cerra M, et al. First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor. Clin Transl Sci. 2021;15(2):330–42. https://doi.org/10.1111/cts.13148.CrossRefPubMedPubMedCentral

32.

Perera V, Abelian G, Li D, Wang Z, Zhang L, Lubin S, et al. Single-dose pharmacokinetics of milvexian in participants with mild or moderate hepatic impairment compared with healthy participants. Clin Pharmacokinet. 2022. https://doi.org/10.1007/s40262-022-01110-9.CrossRefPubMedPubMedCentral

33.

ClinicalTrials.gov. NCT03766581. A study on BMS-986177 for the prevention of stroke in patients receiving aspirin and clopidogrel (AXIOMATIC-SSP). https://clinicaltrials.gov/ct2/show/NCT03766581 Accessed 1 Sep 2020.

34.

Weitz JI, Strony J, Ageno W, Gailani D, Hylek EM, Lassen MR, et al. Milvexian for the prevention of venous thromboembolism. N Engl J Med. 2021;385(23):2161–72. https://doi.org/10.1056/NEJMoa2113194.CrossRefPubMedPubMedCentral

35.

Corpataux N, Spirito A, Gragnano F, Vaisnora L, Galea R, Svab S, et al. Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. Eur Heart J. 2020;41(38):3743–9. https://doi.org/10.1093/eurheartj/ehaa671.CrossRefPubMed

36.

Jackevicius CA, Lu L, Ghaznavi Z, Warner AL. Bleeding risk of direct oral anticoagulants in patients with heart failure and atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2021;14(2):e007230. https://doi.org/10.1161/CIRCOUTCOMES.120.007230.CrossRefPubMed

37.

Vio R, Proietti R, Rigato M, Calo LA. Clinical evidence for the choice of the direct oral anticoagulant in patients with atrial fibrillation according to creatinine clearance. Pharmaceuticals (Basel). 2021;14(3):279. https://doi.org/10.3390/ph14030279.CrossRef

38.

Alhousani M, Malik SU, Abu-Hashyeh A, Poznanski NJ, Al-Hasan S, Roth DF, et al. Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: a systematic review and meta-analysis. Thromb Res. 2021;198:103–14. https://doi.org/10.1016/j.thromres.2020.11.036.CrossRefPubMed

39.

Ocak G, Rookmaaker MB, Algra A, de Borst GJ, Doevendans PA, Kappelle LJ, et al. Chronic kidney disease and bleeding risk in patients at high cardiovascular risk: a cohort study. J Thromb Haemost. 2018;16(1):65–73. https://doi.org/10.1111/jth.13904.CrossRefPubMed

40.

Lutz J, Menke J, Sollinger D, Schinzel H, Thurmel K. Haemostasis in chronic kidney disease. Nephrol Dial Transplant. 2014;29(1):29–40. https://doi.org/10.1093/ndt/gft209.CrossRefPubMed

41.

Hedges SJ, Dehoney SB, Hooper JS, Amanzadeh J, Busti AJ. Evidence-based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol. 2007;3(3):138–53. https://doi.org/10.1038/ncpneph0421.CrossRefPubMed

42.

Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol. 2008;4(8):1065–74. https://doi.org/10.1517/17425255.4.8.1065.CrossRefPubMedPubMedCentral

43.

European Medicines Agency. Committee for Medicine Products for Human Use (CHMP). Note for Guidance on the Evaluation of the Pharmacokinetics of Medicinal Products in Patients with Impaired Renal Function. https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-evaluation-pharmacokinetics-medical-products-patients-impaired-renal-function_en.pdf. Accessed 24 Mar 21.

44.

US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry. Pharmacokinetics in Patients with Impaired Renal Function—Study Design, Data Analysis, and Impact on Dosing and Labeling. https://www.fda.gov/media/71334/download. Accessed 24 Mar 2021.

45.

Wong PC, Crain EJ, Bozarth JM, Wu Y, Dilger AK, Wexler RR, et al. Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: in vitro studies and in vivo evaluation in experimental thrombosis in rabbits. J Thromb Haemost. 2022;20(2):399–408. https://doi.org/10.1111/jth.15588.CrossRefPubMed

46.

Weir MR, Kreutz R. Influence of renal function on the pharmacokinetics, pharmacodynamics, efficacy, and safety of non-vitamin K antagonist oral anticoagulants. Mayo Clin Proc. 2018;93(10):1503–19. https://doi.org/10.1016/j.mayocp.2018.06.018.CrossRefPubMed

47.

Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32(19):2387–94. https://doi.org/10.1093/eurheartj/ehr342.CrossRefPubMed

48.

Zeitouni M, Giczewska A, Lopes RD, Wojdyla DM, Christersson C, Siegbahn A, et al. Clinical and pharmacological effects of apixaban dose adjustment in the ARISTOTLE trial. J Am Coll Cardiol. 2020;75(10):1145–55. https://doi.org/10.1016/j.jacc.2019.12.060.CrossRefPubMed

49.

Dias C, Moore KT, Murphy J, Ariyawansa J, Smith W, Mills RM, et al. Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis. Am J Nephrol. 2016;43(4):229–36. https://doi.org/10.1159/000445328.CrossRefPubMed

50.

Chang M, Yu Z, Shenker A, Wang J, Pursley J, Byon W, et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol. 2016;56(5):637–45. https://doi.org/10.1002/jcph.633.CrossRefPubMed

Title: Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment
Authors: Vidya Perera
Grigor Abelian
Danshi Li
Zhaoqing Wang
Liping Zhang
Susan Lubin
Akintunde Bello
Bindu Murthy
Publication date: 30-07-2022
Publisher: Springer International Publishing
Published in: Clinical Pharmacokinetics / Issue 10/2022
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-022-01150-1

At a glance: The STEP trials

Springer Medicine

Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment

Abstract

Objective

Methods

Results

Conclusion

Clinical Trials Registration

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusion

Clinical Trials Registration

Please log in to get access to this content

Other articles of this Issue 10/2022

Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases

Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review

Evaluation of Safety and Clinically Relevant Drug–Drug Interactions with Tucatinib in Healthy Volunteer﻿s

Clinical Pharmacokinetic Monitoring of Free Valproic Acid Levels: A Systematic Review

Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling

Correction to: Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases

Evaluation of Safety and Clinically Relevant Drug–Drug Interactions with Tucatinib in Healthy Volunteers